Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D; Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017. Lan Z, et al. Among authors: guglielmetti l. Lancet Respir Med. 2020 Apr;8(4):383-394. doi: 10.1016/S2213-2600(20)30047-3. Epub 2020 Mar 17. Lancet Respir Med. 2020. PMID: 32192585 Free PMC article.
Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J; MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort. Guglielmetti L, et al. Clin Infect Dis. 2015 Jan 15;60(2):188-94. doi: 10.1093/cid/ciu786. Epub 2014 Oct 15. Clin Infect Dis. 2015. PMID: 25320286
Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?
Guglielmetti L, Le Dû D, Veziris N, Caumes E, Marigot-Outtandy D, Yazdanpanah Y, Robert J, Fréchet-Jachym M; MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort. Guglielmetti L, et al. Eur Respir J. 2016 Aug;48(2):582-5. doi: 10.1183/13993003.00411-2016. Epub 2016 Jun 23. Eur Respir J. 2016. PMID: 27338196 Free article. No abstract available.
Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
Lange C, Duarte R, Fréchet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, Oliveira O, Rumetshofer R, Veziris N, van Leth F; European MDR-TB database collaboration *. Lange C, et al. Among authors: guglielmetti l. Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031. doi: 10.1164/rccm.201606-1097LE. Am J Respir Crit Care Med. 2016. PMID: 27685538 No abstract available.
Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, Caumes E, Lerat I, Rioux C, Yazdanpanah Y, Tiotiu A, Lemaitre N, Brossier F, Jarlier V, Robert J, Sougakoff W, Aubry A; CNR MyRMA and the Tuberculosis Consilium of the CNR MyRMA; CNR MyRMA and Tuberculosis Consilium of the CNR MyRMA. Veziris N, et al. Among authors: guglielmetti l. Eur Respir J. 2017 Mar 22;49(3):1601719. doi: 10.1183/13993003.01719-2016. Print 2017 Mar. Eur Respir J. 2017. PMID: 28182568 Free article. No abstract available.
150 results